Latest news with #mPress
Miami Herald
06-05-2025
- Business
- Miami Herald
Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time
Press Releases Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones. A press release detailing these results will be issued prior to the call. Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call webcast, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Date: Wednesday, May 14, 2025 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Registration Link: The conference call webcast will be broadcast live and available for replay at the investor relations section of the Company's website here. About Monogram Technologies Inc. Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored. Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances. The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation. To learn more, visit Investor Relations Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 MGRM@ SOURCE: Monogram Technologies Inc.
Associated Press
05-03-2025
- Business
- Associated Press
Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025
AUSTIN, TX / ACCESS Newswire / March 5, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ('Monogram' or the 'Company'), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will participate in the 37th Annual ROTH Conference at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025. Mr. Sexson and Mr. Knape will hold one-on-one meetings with institutional investors on site during this annual invitation-only event. 37th Annual ROTH Conference Date: March 16-18, 2025 Location: Laguna Cliffs Marriott Resort & Spa in Dana Point, CA Attendees: Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape Format: In-person 1x1's Conference Website: Click here For more information on the 37th Annual ROTH Conference or to schedule a one-on-one meeting with Monogram management, please contact your conference representative or you may also email your request to [email protected] or call Chris Tyson at (949) 491-8235. About Monogram Technologies Inc. Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored. Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances. The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation. To learn more, visit Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties.. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Executive Vice President MZ North America
